EA202091015A1 - Новый т-клеточный рецептор - Google Patents
Новый т-клеточный рецепторInfo
- Publication number
- EA202091015A1 EA202091015A1 EA202091015A EA202091015A EA202091015A1 EA 202091015 A1 EA202091015 A1 EA 202091015A1 EA 202091015 A EA202091015 A EA 202091015A EA 202091015 A EA202091015 A EA 202091015A EA 202091015 A1 EA202091015 A1 EA 202091015A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tcr
- cell
- clone
- vector
- agent
- Prior art date
Links
- 108091008874 T cell receptors Proteins 0.000 title abstract 11
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 11
- 239000003795 chemical substances by application Substances 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000002163 immunogen Effects 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1717578.7A GB201717578D0 (en) | 2017-10-26 | 2017-10-26 | Novel T-cell receptor |
| GBGB1806155.6A GB201806155D0 (en) | 2017-10-26 | 2018-04-16 | Novel t-cell receptor |
| PCT/GB2018/053045 WO2019081902A1 (en) | 2017-10-26 | 2018-10-22 | NEW LYMPHOCYTE RECEPTOR T |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202091015A1 true EA202091015A1 (ru) | 2020-07-17 |
Family
ID=60580240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202091015A EA202091015A1 (ru) | 2017-10-26 | 2018-10-22 | Новый т-клеточный рецептор |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11725039B2 (enExample) |
| EP (2) | EP4039700A1 (enExample) |
| JP (1) | JP7289311B2 (enExample) |
| KR (1) | KR20200078497A (enExample) |
| CN (1) | CN111278855B (enExample) |
| AU (2) | AU2018356944A1 (enExample) |
| BR (1) | BR112020007880A2 (enExample) |
| CA (1) | CA3077635A1 (enExample) |
| DK (1) | DK3700925T3 (enExample) |
| EA (1) | EA202091015A1 (enExample) |
| ES (1) | ES2907819T3 (enExample) |
| GB (2) | GB201717578D0 (enExample) |
| IL (1) | IL274025A (enExample) |
| MX (1) | MX2020004334A (enExample) |
| PL (1) | PL3700925T3 (enExample) |
| SG (1) | SG11202002537WA (enExample) |
| WO (1) | WO2019081902A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201717578D0 (en) * | 2017-10-26 | 2017-12-13 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor |
| BR112022013633A2 (pt) * | 2020-01-09 | 2022-09-13 | Biomunex Pharmaceuticals | Anticorpos multiespecíficos que ligam tanto células mait quanto tumorais |
| CN115943307A (zh) * | 2020-01-16 | 2023-04-07 | 巴塞尔大学 | 用于免疫调节的mr1配体和药物组合物 |
| WO2021250511A1 (ko) * | 2020-06-10 | 2021-12-16 | 주식회사 유틸렉스 | Mr1에 결합하는 t-세포 수용체 및 이의 용도 |
| US20230381235A1 (en) * | 2020-11-04 | 2023-11-30 | Fate Therapeutics, Inc. | Multiplexed engineered ipscs and immune effector cells targeting solid tumors |
| WO2022118043A1 (en) | 2020-12-03 | 2022-06-09 | Enara Bio Limited | Novel protein-ligand complex |
| WO2022248881A1 (en) | 2021-05-28 | 2022-12-01 | Enara Bio Limited | Novel protein-ligand complex |
| IL309957A (en) | 2021-07-14 | 2024-03-01 | 2Seventy Bio Inc | Engineered t cell receptors fused to binding domains from antibodies |
| WO2023002204A1 (en) | 2021-07-21 | 2023-01-26 | Enara Bio Limited | T-cell receptor |
| KR20230088292A (ko) * | 2021-12-10 | 2023-06-19 | 주식회사 유틸렉스 | MR1 제한적 Panck T 세포 및 이의 제조방법 |
| WO2023148494A1 (en) | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| KR20250008809A (ko) | 2022-04-08 | 2025-01-15 | 리제너론 파마슈티칼스 인코포레이티드 | 다분할 수용체 및 신호전달 복합체 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI819228B (zh) * | 2013-08-05 | 2023-10-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（八） |
| JP6164759B2 (ja) | 2013-11-21 | 2017-07-19 | Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 | Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用 |
| CN110462024B (zh) * | 2017-03-07 | 2024-08-09 | 巴塞尔大学 | 用于癌症免疫疗法的mr1限制性t细胞受体 |
| GB201717578D0 (en) * | 2017-10-26 | 2017-12-13 | Univ College Cardiff Consultants Ltd | Novel T-cell receptor |
-
2017
- 2017-10-26 GB GBGB1717578.7A patent/GB201717578D0/en not_active Ceased
-
2018
- 2018-04-16 GB GBGB1806155.6A patent/GB201806155D0/en not_active Ceased
- 2018-10-22 MX MX2020004334A patent/MX2020004334A/es unknown
- 2018-10-22 KR KR1020207011102A patent/KR20200078497A/ko not_active Ceased
- 2018-10-22 WO PCT/GB2018/053045 patent/WO2019081902A1/en not_active Ceased
- 2018-10-22 EA EA202091015A patent/EA202091015A1/ru unknown
- 2018-10-22 EP EP21214567.6A patent/EP4039700A1/en not_active Withdrawn
- 2018-10-22 CA CA3077635A patent/CA3077635A1/en active Pending
- 2018-10-22 AU AU2018356944A patent/AU2018356944A1/en not_active Abandoned
- 2018-10-22 PL PL18795783T patent/PL3700925T3/pl unknown
- 2018-10-22 EP EP18795783.2A patent/EP3700925B8/en active Active
- 2018-10-22 CN CN201880069546.9A patent/CN111278855B/zh not_active Expired - Fee Related
- 2018-10-22 JP JP2020543406A patent/JP7289311B2/ja active Active
- 2018-10-22 ES ES18795783T patent/ES2907819T3/es active Active
- 2018-10-22 DK DK18795783.2T patent/DK3700925T3/da active
- 2018-10-22 BR BR112020007880-8A patent/BR112020007880A2/pt unknown
- 2018-10-22 SG SG11202002537WA patent/SG11202002537WA/en unknown
-
2020
- 2020-04-19 IL IL274025A patent/IL274025A/en unknown
- 2020-04-24 US US16/858,082 patent/US11725039B2/en active Active
-
2021
- 2021-01-20 US US17/153,329 patent/US11078252B2/en active Active
-
2024
- 2024-04-26 AU AU2024202735A patent/AU2024202735A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN111278855A (zh) | 2020-06-12 |
| EP4039700A1 (en) | 2022-08-10 |
| US11078252B2 (en) | 2021-08-03 |
| BR112020007880A2 (pt) | 2020-10-27 |
| JP2021500406A (ja) | 2021-01-07 |
| CN111278855B (zh) | 2024-04-02 |
| GB201717578D0 (en) | 2017-12-13 |
| EP3700925B8 (en) | 2022-02-16 |
| US20200369742A1 (en) | 2020-11-26 |
| ES2907819T3 (es) | 2022-04-26 |
| JP7289311B2 (ja) | 2023-06-09 |
| EP3700925A1 (en) | 2020-09-02 |
| EP3700925B1 (en) | 2021-12-29 |
| PL3700925T3 (pl) | 2022-05-02 |
| IL274025A (en) | 2020-06-30 |
| US11725039B2 (en) | 2023-08-15 |
| DK3700925T3 (en) | 2022-04-04 |
| SG11202002537WA (en) | 2020-05-28 |
| AU2018356944A1 (en) | 2020-04-16 |
| US20210147506A1 (en) | 2021-05-20 |
| KR20200078497A (ko) | 2020-07-01 |
| MX2020004334A (es) | 2020-08-03 |
| GB201806155D0 (en) | 2018-05-30 |
| WO2019081902A1 (en) | 2019-05-02 |
| AU2024202735A1 (en) | 2024-05-30 |
| CA3077635A1 (en) | 2019-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202091015A1 (ru) | Новый т-клеточный рецептор | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
| MX2018007406A (es) | Anticuerpos anti-lag3 y fragmentos de enlace al antigeno. | |
| PH12018500363A1 (en) | Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| MX2018010473A (es) | Terapia de combinacion con anticuerpos anti cumulo de diferenciacion 73 (cd73). | |
| EP4406554A3 (en) | Anti-cd3 antibody formulations | |
| MY197324A (en) | Adenovirus armed with bispecific t cell activator | |
| PH12017501166A1 (en) | Antibodies to tight | |
| MY196646A (en) | Agonistic Antibodies Specifically Binding Human CD40 And Methods of use | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| MX2018003936A (es) | Anticuerpos anti proteina de muerte celular programada 1 (pd-1) y composiciones. | |
| EA201791560A1 (ru) | Порошковый состав для интраназального введения для лечения гипогликемии | |
| EA202091276A1 (ru) | Новый гамма дельта т-клеточный рецептор и его лиганд | |
| MY187050A (en) | Cancer cell-specific antibody, anticancer agent, and cancer testing method | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| MX2020005495A (es) | Anticuerpo anti-vista y uso del mismo. | |
| MX2021005085A (es) | Formulacion de anticuerpo. | |
| EA202090565A1 (ru) | Композиции и способы лечения диффузной в-крупноклеточной лимфомы | |
| MX2020013601A (es) | Receptores de las celulas t especificos de cancer. | |
| EA202190045A1 (ru) | Составы/композиции, содержащие ибрутиниб | |
| NZ719745A (en) | Soluble fc gamma receptor for treatment of autoimmune bullous diseases | |
| HK1248256A1 (zh) | L型电压门控通道抗体及其相关方法 | |
| EA201991336A1 (ru) | Способы лечения рака с помощью антител к pd-1 |